Delcath Systems, Inc. (DCTH) Resumes Enrollment in Phase II and Phase III Clinical Trials
Delcath Systems, Inc (DCTH) announced that the U.S. Food and Drug Administration has informed the company that patient enrollment can now resume in the company's Phase II and Phase III clinical trials of the Delcath System. Through Delcath's various meetings with both the FDA and the Principal Investigator of the National Cancer Institute, all parties have approved such an action. Current clinical trial sites, already informed that the study can resume immediately, will began testing patients immediately. Previously, adverse events were observed in four patients enrolled in the Delcath System on October 23, 2007. As a result, the FDA launched…